Inside Innovation

Seattle biotech startup Parse Biosciences received $50 million in funding from a Series C equity round. Capitalist firms including Soleus Capital, Marshall Wace and Bioeconomy

Seattle will be the site of a new Prenuvo clinic, a full-body imaging company from Silicon Valley specializing in MRI scans. The company’s full-body machine,

Redmond-based biotech company Systimmune has secured an exclusive license and collaboration agreement with Bristol Myers Squibb (BMS) to support the development of its solid tumor

Pfizer’s pending acquisition of Seattle-based biotech company Seagen closed on December 14th, according to an announcement from Pfizer. Amid the newly approved deal, Pfizer plans

AstraZeneca announced that it will pay up to $1.1 billion to acquire Seattle-based biotechnology company Icosavax. Spun out of the Institute for Protein Design at

A new biotech company called BrainChild Bio was created by Seattle Children’s Clinic. The company’s focus is a CAR T-cell therapy initiative aimed at treating

The Seattle Hub for Synthetic Biology (the Hub), a new biotech company specializing in self-monitoring cells, received $75 million to support its collaboration with University

Nadia Dac, Omeros Corporation’s chief commercial officer, was named one of the top 50 women leaders of Seattle by Women We Admire. Dac has nearly

Biotech company Absci, based in Vancouver, Washington, is teaming up with AstraZeneca to create antibody therapeutics to combat cancer. The deal is worth over $200

Seattle-based biotech company Lumen Bioscience (Lumen) received $5.5 million from the U.S. Department of Defense to support its research and development of needleless vaccines. Lumen’s

The Paul G. Allen Family Foundation, based in Seattle, is awarding roughly $10.5 million to several research initiatives. Established in 1988, the foundation funds projects